This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical siteSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Example content

Adverse event reporting can be found at the bottom of the page

Featured articles

 Oncology

Changing the course of multiple myeloma

Multiple myeloma survival rates have improved over the past 50 years in the UK, yet challenges still remain when managing the relapsing-remitting condition. Here, we cover some of these challenges, and share Pfizer's commitment to the myeloma community. Read

Published April 2024.

 Oncology

Looking back on cancer advances in 2023

An overview of the world of Oncology in 2023 – from better understanding of the complex biology of cancer, to a record-breaking year for NHS cancer check-ups. Read

Published February 2024.

Comming soon

A UK perspective on antimicrobiral resitance and stewardship

The recent two years have been overshadowed by viral pandemics with nations providing rapid responses to contain the spread. It might now be the right time to renew our focus on other devastating infection risks. One of them is the ever-increasing emergence of antimicrobial resistance (AMR) which makes it more difficult to treat these effectively. Coming soon

Published December2023.

 Antimicrobial Resistance

A UK perspective on antimicrobial resistance and stewardship

Recent years have been overshadowed by the viral pandemic, with nations providing rapid responses to contain the spread. It might now be the right time to renew our focus on other devastating infection risks. One of them is the ever-increasing emergence of antimicrobial resistance (AMR) which makes it more difficult to treat resistant bacterial infections effectively. Read

Published December 2023.

Comming soon

A UK perspective on antimicrobiral resitance and stewardship

The recent two years have been overshadowed by viral pandemics with nations providing rapid responses to contain the spread. It might now be the right time to renew our focus on other devastating infection risks. One of them is the ever-increasing emergence of antimicrobial resistance (AMR) which makes it more difficult to treat these effectively. Coming soon

Published December2023.

Innovative Medicines

Supporting ICBs with system transformation 

A system-wide approach is required across the whole pathway of care. With medicines being a core component of patient pathways, systematisation provides an opportunity to review where medicines can be most effectively prescribed.
 

 Read

Published November 2023.

 Breast Cancer

Breast Cancer in the UK: where are we now?

During Breast Cancer Awareness Month we took the time to celebrate advances made in the management of this condition. Pfizer remains firmly committed to improving patient outcomes in breast cancer. Read

Published October 2023.

 Blood Cancer

Towards better outcomes in the UK

More people are surviving a diagnosis of blood cancer today than ever before, but there is still work to be done.

Read about Pfizer's commitment to continually improving outcomes for people living with blood cancer.  Read

Published September 2023.

Population Health

Integrated approaches to primary care

There was a huge increase in demand for accessing primary care services last winter. Upcoming winters may well be worse without intervention and learning from the past. In this article we discuss the action plan for recovery in primary care.

 

 Read

Published June 2023.

 Demand Management

Addressing waitlists and service backlogs

In 2023 the Government reiterated that reducing NHS waiting lists was a key priority for 2023. In this article we look at the delivery plan for addressing the backlog.  Read

Published June 2023.

 Health Inequalities

Partnership working

Addressing health inequalities through population health is a vital component of successful integrated care strategies. In this article, we explore which aspects of population health could be impacted and how this might be achieved. Read

Published February 2023.

PP-UNP-GBR-8628 April 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​